Space pharmaceuticals—A "new scenario" for commercial aerospace

Space pharmaceuticals—A "new scenario" for commercial aerospace

The space economy over the past ten-plus years has resembled two businesses: sending things up (rockets and infrastructure), and selling signals back down (satellite communications). Morgan Stanley pushed the perspective a step forward: as reusable rockets drive down the "cost of going to space," business opportunities may expand from "transportation" to "production," with pharmaceuticals being the most promising sector to emerge first.

According to Wind-chasing Trading Desk, Morgan Stanley analyst Adam Jonas stated in a recent report that space pharmaceutical manufacturing is becoming commercially viable thanks to reusable rockets reducing launch costs by about tenfold. Varda Space is a pioneer in this field—it designs and launches spacecraft to manufacture drugs in low Earth orbit, utilizing the microgravity environment to produce high-purity pharmaceutical crystals impossible to achieve on Earth.

The report notes that the logic of space pharmaceuticals is straightforward: drug crystals grow more uniformly, with fewer defects and higher purity in microgravity. In 1998, the insulin crystals cultivated during Space Shuttle STS-95 were on average 34 times the volume of those on Earth, with seven times fewer defects.

Varda successfully completed its first commercial mission in 2024, bringing HIV drug Ritonavir crystals back from orbit. The company has raised $328 million, with the latest round led by Natural Capital and Shrug Capital, and investors including Peter Thiel, Founders Fund, etc. Varda plans to achieve near-monthly return frequency by the end of 2028, having completed five missions so far, with the sixth scheduled for March this year.

The road is still full of obstacles: the FDA has yet to establish approval processes for space pharmaceuticals, unit economics are unproven, and mass commercialization requires weekly or even daily launch cadence.

For space manufacturing to become an industry, the "elevator" must keep getting cheaper

The report gives an engineering reason for "why talk about space manufacturing now": reusable rockets are like elevators, and have lowered launch costs per kilogram by about tenfold, estimated by Morgan Stanley (Falcon 9 at about $2,000–4,000 per kg).

If larger and more thoroughly reusable next-generation launch vehicles further improve economics, they can push "doing something in space" from scientific demonstrations to commercially viable activities—not just pharmaceuticals, but materials, computing, energy, mining, defense, and more.

But the report also clearly sets boundaries: even with cheaper launches, much space manufacturing is still stuck on regulatory complexity, process control, recovery logistics, and demand validation. Its decades-long lack of commercialization is not due to lack of interest, but because the chain is too long, with too many steps.

Why pharmaceuticals may lead: microgravity has clear benefits for "crystal quality"

Varda does not develop new drugs or new drug molecules. Its business model is to manufacture high-purity, high-density versions of existing drugs for large pharmaceutical clients.

The Morgan Stanley report states:

Most pharmaceuticals, especially tablets, are made from tiny drug crystals. The shape and quality of the crystals directly affect the drug's dissolution rate, absorption efficiency, stability, and manufacturability. On Earth, gravity-driven convection, sedimentation, and mixing interfere with crystal growth, resulting in uneven sizes and high defect density.

The microgravity environment of low Earth orbit virtually eliminates convection and sedimentation, allowing crystals to grow more orderly. Merck's research on the International Space Station showed that crystals of cancer drug pembrolizumab (Keytruda) grown in space may allow intravenous delivery to be replaced by a simple injection. Some drugs trap impurities in the crystal structure during crystallization, leading to toxic side effects, whereas the slower, more uniform crystallization process in space makes impurity separation easier.

This logic corresponds to three potential benefits in the report: first, improving API purity and density; second, enhancing drug stability, shelf life, and bioavailability; third, enabling new choices for certain dosage forms and administration methods.

Winnebago spacecraft: a one-meter-diameter space factory

Varda’s method of screening candidate drugs involves using a supergravity crystallization platform (large centrifuge device) on Earth to alter effective gravity, observing how gravity changes affect nucleation and crystal growth behavior, quickly identifying gravity-sensitive drug molecules.

The Morgan Stanley report details Varda's W series (nicknamed "Winnebago"), a free-flying orbital processing and return system. It weighs about 300 kg, with mission cycles lasting several weeks to months, designed to withstand re-entry speeds over Mach 25.

The system consists of two parts: a 1-meter-diameter re-entry capsule housing the manufacturing payload, returning to land under a parachute; a satellite bus providing in-orbit power, communications, attitude control, and propulsion, including deorbit positioning before re-entry.

Why so small? Because it only manufactures active pharmaceutical ingredients (API), which usually make up only a small part of the drugs ultimately delivered to patients. Producing API in space doesn't require large volumes to achieve commercial relevance. Smaller batches also let pharma clients repeatedly iterate and optimize production. The small design means the spacecraft can hitch rides on Falcon 9 shared missions, crucial for lowering launch costs and enabling high-frequency flights.

Five missions: from verification to acceleration

The reported progress is more about "getting the cycle running smoothly" than "drugs are already on the market."

  • W-1 (2023/6–2024/2): Crystallized Ritonavir in orbit and recovered it, the key proof-of-concept for the business model; return capsule landed at the U.S. Utah Test and Training Range.
  • W-2, W-3 (2025): Beyond pharmaceutical payloads, carried additional hypersonic/re-entry-related payloads for Air Force Research Lab, recovery locations include Koonibba Test Range, Australia.
  • W-4 (from 2025/6): Began using its own satellite platform, conducting longer in-orbit manufacturing experiments (drugs and semiconductor processes).
  • W-5 (2025/11–2026/1): Completed re-entry and recovery on January 29, 2026; achieved the first full cycle using its vertically integrated satellite platform from in-orbit operations to capsule recovery.

On the regulatory front, the report mentions Varda obtained FAA Part 450 re-entry permits (extended to operational permits through 2029), allowing it to perform return missions more routinely; the company has publicly stated its goal of reaching nearly "monthly returns" by the end of 2028, with long-term plans even more aggressive (weekly or daily), and the next W-6 mission tentatively set for March 2026.

Real challenges: unit economics, launch frequency, process stability, and how FDA inspects factories

The report lists four "hard constraints" for commercialization, most centering on logistics and compliance:

  • Unit economics uncertain: The per-kilogram cost for launch, in-orbit operations, and re-entry recovery is still high; must rely on "high-value density" products. Whether they can achieve profitable scale remains unproven, and significant revenue may require heavy capital investment beforehand.
  • Dependence on high-frequency launches: Revenue for such companies is tightly tied to "how much physical output can be returned each time." To scale, they need frequent, reliable launch and recovery cadence.
  • Process control difficulties: Vacuum, temperature variation, radiation, and microgravity itself make process stability and repeatability harder. Even successful experiments need repeated iteration before resembling industrial production.
  • Unsolved FDA approval and CGMP inspection issues: The report explicitly states there are currently no FDA approvals for "space-manufactured drugs" intended for human use. According to current logic, they still need to go through standard NDA processes, using clinical data to prove safety and efficacy. As for CGMP inspection, with "factories moved to orbit," execution is complex; legal experts guess it may require remote assessments similar to those used during pandemics, but for Varda's "orbit for weeks/months then recovery" model, entirely new methods may be needed.

The core message of the report is simple: the space economy does not have to forever just sell "sending things up" and "bringing signals down." Once launches become cheaper, recovery becomes routine, and regulatory paths are established, pharmaceuticals may be among the first industries to write "space manufacturing" into commercial statements instead of scientific stories; Varda is just the fastest current example running this cycle.

 

~~~~~~~~~~~~~~~~~~~~~~~~

The above content is from Wind-chasing Trading Desk.

For more detailed interpretation, including real-time commentary, first-hand research, etc., please join [Wind-chasing Trading Desk ▪ Annual Membership]

Risk Disclaimer and Exemption ClauseThe market carries risks; investments require caution. This article does not constitute personal investment advice, nor does it take into account the unique investment goals, financial situation, or needs of individual users. Users should consider whether any opinions, viewpoints, or conclusions in this article fit their particular situation. If you invest based on this, you bear responsibility.